2seventy bio logo

2seventy bioNASDAQ: TSVT

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

03 November 2021

Next earnings report:

14 November 2024

Last dividends:

N/A

Next dividends:

N/A
$220.41 M
-77%vs. 3y high
54%vs. sector
-vs. 3y high
-vs. sector
-53%vs. 3y high
40%vs. sector
-75%vs. 3y high
61%vs. sector

Price

after hours | Fri, 01 Nov 2024 23:25:32 GMT
$4.28-$0.15(-3.39%)

Dividend

No data over the past 3 years
$8.97 M$15.04 M
$8.97 M$24.88 M

Analysts recommendations

Institutional Ownership

TSVT Latest News

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 2seventy bio, Inc. - TSVT
prnewswire.com02 November 2024 Sentiment: NEGATIVE

NEW YORK , Nov. 2, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  2seventy bio, Inc. ("2seventy bio" or the "Company") (NASDAQ: TSVT).  Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 2seventy bio, Inc. - TSVT
accesswire.com31 October 2024 Sentiment: NEGATIVE

NEW YORK, NY / ACCESSWIRE / October 31, 2024 / Pomerantz LLP is investigating claims on behalf of investors of 2seventy bio, Inc. ("2seventy bio" or the "Company")(NASDAQ:TSVT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 2seventy bio, Inc. - TSVT
accesswire.com27 October 2024 Sentiment: NEGATIVE

NEW YORK, NY / ACCESSWIRE / October 27, 2024 / Pomerantz LLP is investigating claims on behalf of investors of 2seventy bio, Inc. ("2seventy bio" or the "Company")(NASDAQ:TSVT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 2seventy bio, Inc. - TSVT
accesswire.com19 October 2024 Sentiment: NEGATIVE

NEW YORK, NY / ACCESSWIRE / October 19, 2024 / Pomerantz LLP is investigating claims on behalf of investors of 2seventy bio, Inc. ("2seventy bio" or the "Company")(NASDAQ:TSVT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 2seventy bio, Inc. - TSVT
prnewswire.com17 October 2024 Sentiment: NEGATIVE

NEW YORK , Oct. 17, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of 2seventy bio, Inc. ("2seventy bio" or the "Company") (NASDAQ: TSVT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 2seventy bio, Inc. - TSVT
accesswire.com15 October 2024 Sentiment: NEGATIVE

NEW YORK, NY / ACCESSWIRE / October 15, 2024 / Pomerantz LLP is investigating claims on behalf of investors of 2seventy bio, Inc. ("2seventy bio" or the "Company")(NASDAQ:TSVT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 2seventy bio, Inc. - TSVT
accesswire.com11 October 2024 Sentiment: NEGATIVE

NEW YORK, NY / ACCESSWIRE / October 11, 2024 / Pomerantz LLP is investigating claims on behalf of investors of 2seventy bio, Inc. ("2seventy bio" or the "Company")(NASDAQ:TSVT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

2seventy bio, Inc. INVESTIGATION: Levi & Korsinsky Investigates Potential Securities Fraud by 2seventy bio, Inc. (TSVT)
accesswire.com10 October 2024 Sentiment: NEGATIVE

NEW YORK, NY / ACCESSWIRE / October 10, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of 2seventy bio, Inc. ("2seventy bio, Inc.") (NASDAQ:TSVT) concerning possible violations of federal securities laws. 2seventy bio issued a press release on September 25, 2024, announcing that it "will discontinue enrollment in its ongoing Phase 3 KarMMa-9 study evaluating Abecma® (idecabtagene vicleucel; ide-cel) with lenalidomide maintenance versus lenalidomide maintenance alone in patients with newly diagnosed multiple myeloma (NDMM) who have suboptimal response to autologous stem cell transplant.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 2seventy bio, Inc. - TSVT
prnewswire.com09 October 2024 Sentiment: NEGATIVE

NEW YORK , Oct. 9, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of 2seventy bio, Inc. ("2seventy bio" or the "Company") (NASDAQ: TSVT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

Did 2seventy bio, Inc. Mislead Investors? Shareholder Rights Advocates at Levi & Korsinsky Investigate- TSVT
accesswire.com09 October 2024 Sentiment: NEGATIVE

NEW YORK, NY / ACCESSWIRE / October 9, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of 2seventy bio, Inc. ("2seventy bio, Inc.") (NASDAQ:TSVT) concerning possible violations of federal securities laws. 2seventy bio issued a press release on September 25, 2024, announcing that it "will discontinue enrollment in its ongoing Phase 3 KarMMa-9 study evaluating Abecma® (idecabtagene vicleucel; ide-cel) with lenalidomide maintenance versus lenalidomide maintenance alone in patients with newly diagnosed multiple myeloma (NDMM) who have suboptimal response to autologous stem cell transplant.

What type of business is 2seventy bio?

2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma. It has a collaboration arrangement with Bristol Myers Squibb Company. The company was incorporated in 2021 and is headquartered in Cambridge, Massachusetts.

What sector is 2seventy bio in?

2seventy bio is in the Healthcare sector

What industry is 2seventy bio in?

2seventy bio is in the Biotechnology industry

What country is 2seventy bio from?

2seventy bio is headquartered in United States

When did 2seventy bio go public?

2seventy bio initial public offering (IPO) was on 03 November 2021

What is 2seventy bio website?

https://www.2seventybio.com

Is 2seventy bio in the S&P 500?

No, 2seventy bio is not included in the S&P 500 index

Is 2seventy bio in the NASDAQ 100?

No, 2seventy bio is not included in the NASDAQ 100 index

Is 2seventy bio in the Dow Jones?

No, 2seventy bio is not included in the Dow Jones index

When was 2seventy bio the previous earnings report?

No data

When does 2seventy bio earnings report?

The next expected earnings date for 2seventy bio is 14 November 2024